NYSE:ANVS

Annovis Bio (ANVS) Stock Price, News & Analysis

Annovis Bio logo
$0.71 -0.04 (-5.33%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$0.73 +0.02 (+2.82%)
As of 11/20/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Annovis Bio Stock (NYSE:ANVS)

Advanced

Key Stats

Today's Range
$0.70
▼
$0.77
50-Day Range
$0.65
▼
$1.39
52-Week Range
$0.62
▼
$5.50
Volume
1.43 million shs
Average Volume
3.61 million shs
Market Capitalization
$44.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Hold

Company Overview

Annovis Bio is a clinical-stage biotechnology company based in Malvern, Pennsylvania. Founded in 2008, the company researches and develops treatments for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease.

AI Generated. May Contain Errors.

Annovis Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
71st Percentile Overall Score

ANVS MarketRank™: 
3.56530898876 of 5 stars

Annovis Bio scored higher than 71% of companies evaluated by MarketBeat, and ranked 172nd out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Annovis Bio has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Annovis Bio has a consensus price target of $10.00, representing about 1,308.5% upside from its current price of $0.71.

  • Amount of Analyst Coverage

    Annovis Bio has only been the subject of 2 research reports in the past 90 days.

  • Read more about Annovis Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Annovis Bio are expected to grow in the coming year, from ($1.29) to ($0.63) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Annovis Bio is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Annovis Bio is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    14.81% of the float of Annovis Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Annovis Bio has a short interest ratio ("days to cover") of 6.77.
  • Change versus previous month

    Short interest in Annovis Bio has recently decreased by 6.38%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Annovis Bio does not currently pay a dividend.

  • Dividend Growth

    Annovis Bio does not have a long track record of dividend growth.

  • News Sentiment

    Annovis Bio has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Annovis Bio this week, compared to 1 article on an average week.
  • Search Interest

    10 people have searched for ANVS on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Annovis Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $5,000,000.00 in company stock, which represents 11.3543% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Annovis Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,000,000.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    15.92% of the stock of Annovis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    15.83% of the stock of Annovis Bio is held by institutions.

  • Read more about Annovis Bio's insider trading history.
Receive ANVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ANVS Stock News Headlines

Prediction: NVDA will “snap back” on this date
Others paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access for just $7. The specialized indicator shows when a stock is likely to "snap back," helping traders avoid buying at the peak. It can also flag when a stock may bounce off the bottom so you can time your entry. Run NVDA or any other popular AI stock through it before you place a trade.tc pixel
Annovis Bio (NYSE:ANVS) Earns "Buy" Rating from Roth Capital
See More Headlines

ANVS Stock Analysis - Frequently Asked Questions

Annovis Bio's stock was trading at $3.43 at the start of the year. Since then, ANVS stock has decreased by 79.3% and is now trading at $0.71.

Annovis Bio, Inc. (NYSE:ANVS) issued its quarterly earnings results on Friday, November, 13th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.08.

Annovis Bio (ANVS) raised $12 million in an initial public offering on Thursday, November 18th 2021. The company issued 2,000,000 shares at $6.00 per share.

Annovis Bio's top institutional shareholders include Marshall Wace LLP (3.95%), State Street Corp (0.24%), Empowered Funds LLC (0.08%) and StoneX Group Inc. (0.06%). Insiders that own company stock include Michael B Hoffman and Maria-Luisa Maccecchini.
View institutional ownership trends
.

Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Annovis Bio investors own include NVIDIA (NVDA), Cassava Sciences (FLNA), Anavex Life Sciences (AVXL), Advanced Micro Devices (AMD), Micron Technology (MU), Dell Technologies (DELL) and Altimmune (ALT).

Company Calendar

Last Earnings
11/13/2026
Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NYSE:ANVS
CIK
1477845
Fax
N/A
Employees
7
Year Founded
2008

Price Target and Rating

High Price Target
$17.00
Low Price Target
$3.00
Potential Upside/Downside
+1,308.5%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$28.85 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-8,315.60%
Return on Assets
-318.95%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.88
Quick Ratio
3.47

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.21) per share
Price / Book
-3.38

Miscellaneous

Outstanding Shares
62,023,000
Free Float
52,149,000
Market Cap
$44.04 million
Optionable
Optionable
Beta
1.36

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NYSE:ANVS) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners